PARIS, May 31, 2021 (GLOBE NEWSLETTER) — Onxeo SA. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), «Onxeo», a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA damage response (DDR) in oncology, today announced the formation of a new Scientific Advisory Committee of leading scientific and clinical experts in DDR, treatment resistance and more globally, drug development in oncology. The Committee will advise and guide the Company in the development of its proprietary platform of compounds in DDR and the development of innovative therapies that address unmet medical needs and improve the treatment of cancer patients.
“We feel excited and privileged to be working with this eminent group of renowned opinion leaders in oncology,” said Judith Greciet, Onxeo’s Chief Executive Officer. “Their scientific advice and clinical expertise will be extremely helpful in determining the best development strategies for AsiDNA™ and in exploiting its unique properties. In addition, their support will be particularly valuable to design new and differentiated candidates from our platON™ platform to enrich our pipeline of decoy agonists.”
Gilbert Chue, MD, PhD, professor of medicine (oncology) and biochemistry at Stanford Medical School, noted: “The decoy agonist technology Onxeo is developing is a promising new approach to hijack the DNA damage response for cancer treatment. AsiDNA™ has attractive and original anti-tumor properties that could lead to new therapeutic strategies, especially for cancers with high unmet medical need.”
Gilles Favre, PharmD, medical biologist, PhD, director of CRCT (Toulouse Research Center in Cancerology), concluded: “Onxeo addresses a major unmet need in cancer treatment, which is to prevent or reverse tumor drug resistance. The early work our team has done to combine AsiDNA™ with targeted therapies has shown promising results, and I look forward to working with my leading colleagues to help advance these developments.”
The Scientific Advisory Committee will consist of the following members:
Gilbert Chue, MD, PhD, is a professor of medicine (oncology) and biochemistry at Stanford Medical School. He received a BA in physics from Princeton University in 1967, a Ph.D. in physics from MIT in 1973 and an MD from Harvard Medical School in 1980. Gilbert Chu joined the Stanford faculty in 1987. His notable contributions include discovering and characterizing proteins involved in DNA repair and developing tools for assessing toxicity associated with cancer chemotherapy. His research has also examined how cells respond to DNA damage from radiation and chemotherapy.
Gilles Favre, PharmD, medical biologist, PhD, director of the CRCT (Toulouse Research Center in Cancerology), is currently professor of biochemistry and biomedicine at the University of Toulouse and director of the laboratory of clinical and genetic oncology at the Institut Universitaire du Cancer de Toulouse -Oncopole, for which he is scientific director. His research focuses on cancer cell signaling leading to identification of therapeutic targets and translational medicine-based approaches to discover novel biomarkers. Recently, his work has focused on reversing resistance to targeted therapy in lung cancers and melanomas.
Lorenzo Galluzzi, PhD, is assistant professor of cell biology in radiotherapy in the radiotherapy division of Weill Cornell Medical College (New York, NY, USA), honorary assistant professor adjunct at Yale School of Medicine (New Haven, CT, USA), Honorary Associate Professor at the Faculty of Medicine of the University of Paris (Paris, France), and faculty member at several universities in Italy (Ferrara, Padova, Rome). Lorenzo Galluzzi is best known for his major experimental and conceptual contributions in the fields of tumor metabolism and tumor immunology, the links between adaptive stress responses in cancer cells and the activation of a clinically relevant tumor-targeted immune response.
Ruth Plummer, FMedSci, MD, PhD, is Professor of Experimental Cancer Medicine at the Northern Institute for Cancer Research, Newcastle University and Honorary Adviser in Medical Oncology at Newcastle Hospitals NHS Foundation Trust. She heads the Newcastle Experimental Cancer Medicine Center and also the CRUK Newcastle Cancer Centre. She runs a practice for anyone entering Phase I and takes responsibility for one of the most active Phase I departments in the UK. Her research interests are in DNA repair and early stage clinical trials of new agents, with the first PARP inhibitor in the clinic in 2003, ATR inhibitor in 2012, and MCT1 inhibitor in 2014. Her work has contributed to the development and validation of pharmacokinetic and pharmacodynamic tests in early clinical drug development, tests that are now embedded in early phase trial design.
caroline robert, MD, Ph.D., is the chief of the dermatology department at Gustave Roussy and co-director of the Melanoma Research Unit at Paris-Sud University. She was educated at Paris V University, France, and completed a research fellowship at Harvard, Brigham & Women’s Hospital in Cancer Immunology and Immunotherapy. Her main focuses are clinical and translational research on immunotherapy and targeted therapy. Caroline Robert is the national and international coordinator of many clinical trials of targeted therapy and immunotherapy from phase I to III. Her recent work has focused on the identification of novel biomarkers for immunotherapy and targeted therapies of patients with melanoma.
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs that target the DNA-binding functions of tumors through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The company is focused on bringing first-class or disruptive compounds from early-stage translational research to clinical proof-of-concept, a value-creating inflection point that is attractive to potential partners.
flatON™ is Onxeo’s proprietary chemistry platform of oligonucleotides that act as decoy agonists, generating new innovative compounds and broadening the company’s product pipeline.
AsiDNA™, the first compound of platON™, is a first-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism that acts upstream of multiple DDR pathways. Translational research has uncovered the distinctive properties of AsiDNA™, in particular its ability to override tumor resistance to PARP inhibitors, regardless of genetic mutation status. AsiDNA™ has also shown strong synergy with other tumor DNA damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVeneus) phase I study evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed its active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is evaluating the safety and efficacy of AsiDNA™ at a dose of 600 mg in combination with the reference chemotherapy, carboplatin -/+ paclitaxel, in advanced metastatic tumors. Preliminary results from both cohorts showed good tolerability, disease stabilization and an increase in treatment duration compared to previous treatments. The ongoing REVOCAN phase 1b/2 study is evaluating the effect of AsiDNA™ on acquired resistance to PARP inhibitor niraparib in relapsed ovarian cancer (sponsored by Gustave Roussy). A Phase 1b/2 study, AsiDNA™ Children, will be initiated in 2021 to evaluate the association of AsiDNA™ with radiotherapy in children with relapsed high-grade glioma (sponsored by Institut Curie).
OX401 is a new drug candidate from platON™ optimized to be a next-generation PARP inhibitor that acts on both the DNA damage response and the activation of the immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies alone and in combination with immunotherapies.
For more information, visit www.onxeo.com.
This communication expressly or impliedly contains certain forward-looking statements regarding Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors that could cause the actual results, financial condition, performance or performance of Onxeo to differ materially from any future results, performance or performance expressed or implied by such forward-looking statements. Onxeo is providing these communications as of this date and makes no commitment to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties that could cause the actual results, financial condition, performance or performance of Onxeo to differ from those in the forward-looking statements, please refer to the risk factors described in the company’s most recent registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (www.onxeo.com) and/or the AMF (www.amf-france.org).
+33 1 45 58 76 00Media relations
+33 1 44 71 94 98
Investor Relations / Strategic
Dusan Oresanský / Emmanuel Huynh
+33 1 44 71 94 92
Certified Advisor for Nasdaq First North
+45 89 88 78 46